Ultivue

Ultivue Announces Co-Marketing Agreement with Sirona DX for Multiplexed Tissue Biomarker Solutions for Precision Medicine

Retrieved on: 
Tuesday, March 15, 2022
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, CRO, Solution, Proteomics, Genomics, Immunotherapy, Doctor of Philosophy, Drug discovery, Partnership, Corporate development, Research, Drug development, MIF, Industry, Precision medicine, Workflow, Pathology, Medical imaging, Fine chemical, Sutro Biopharma, Sirona Dx, Ultivue, SIRONA DX, ULTIVUE

Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics.

Key Points: 
  • Ultivue, a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique solutions for use in both multiplex immunofluorescence (mIF) imaging and spatial phenomics.
  • Sirona Dx are original pioneers of spatial biology, having launched ultra-high parameter, multiplexed imaging services to Biopharma in 2018.
  • We are delighted to announce this partnership with Ultivue said Andrew Brown, Ph.D. Chief Commercial Officer at Sirona Dx.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.

Ultivue Announces Co-Marketing Agreement with Aignostics for Unique Spatial AI-Powered Imaging Solutions for Translational Medicine

Retrieved on: 
Wednesday, March 9, 2022
Software, Research, General Health, Pharmaceutical, Oncology, Data Management, Technology, Genetics, Science, Biotechnology, Other Science, Health, Industry, Clinical trial, Pathology, Partnership, Research, Workflow, Artificial intelligence, Precision medicine, IHC, H&E, GCP, Solution, Technology, Cdx, MIF, CEO, Algorithm, NSCLC, Medical imaging, Pharmaceutical industry, Sutro Biopharma, Technical University of Berlin, Ultivue, Aignostics, ULTIVUE, AIGNOSTICS

These results will be published later this year and respective AI models made available via the platform.

Key Points: 
  • These results will be published later this year and respective AI models made available via the platform.
  • We are excited to start offering this approach to our clients for translational science and clinical trials, said Viktor Matyas, CEO of Aignostics.
  • Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology.
  • These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.

prismCDX Implements Ultivue’s UltiMapper™ Platform for Standardized, Comprehensive Cancer Tissue Phenotypic Characterization

Retrieved on: 
Friday, November 8, 2019
Science, Software, Biotechnology, Research, Internet, Oncology, Health, Technology, Branches of biology, Medicine, Clinical medicine, Cell biology, Biotechnology, Biomarkers, Omics, Laboratory techniques, Precision medicine, Biopsy, Assay, Proteomics, prismCDX, Ultivue

The addition of Ultivues highly standardized multiplex tissue marker assays enables the identification of critical cellular phenotypes and tissue marker signatures in support of translational and clinical research programs.

Key Points: 
  • The addition of Ultivues highly standardized multiplex tissue marker assays enables the identification of critical cellular phenotypes and tissue marker signatures in support of translational and clinical research programs.
  • The combination of Ultivues next generation tissue marker assays with our platforms for genomic and proteomic analysis provides novel biological insights into the characterization of individual tumor microenvironments, commented Dong-Jun Bae, CEO with prismCDX.
  • Such complete tumor profiling and characterization data support our mission at prismCDX to partner with biopharma organizations developing targeted, precision medicine therapies and associated companion diagnostic tests.
  • Ultivues UltiMapper multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows.

Targos and Ultivue Partner to Incorporate Highly Standardized UltiMapper™ Tissue Multiplex Phenotypic Assays in Support of Clinical Research Services

Retrieved on: 
Thursday, November 7, 2019
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Natural sciences, Laboratory techniques, Chemistry, Biotechnology, Biomarkers, Assay, Biochemistry, Titration, Multiplex, Targos, Ultivue

The adoption of highly standardized multiplex tissue biomarker assays is a strategic fit with our mission to continuously improve the success of clinical trials and deliver exceptional value to our biopharma partners.

Key Points: 
  • The adoption of highly standardized multiplex tissue biomarker assays is a strategic fit with our mission to continuously improve the success of clinical trials and deliver exceptional value to our biopharma partners.
  • Ultivue technologies and UltiMapper assays are widely used in tumor immune-profiling research strategies by the biomedical community to demonstrate the clinical utility of panels of markers.
  • Targos also offers highly customizable UltiMapper panels that can be used in combination with the companys broad menu of additional assays and end-to-end quality services.
  • Translational and clinical researchers leverage UltiMapper assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools.